WO2012076409A1 - Multipurpose gel for vaginal dryness with direct and delayed effect - Google Patents
Multipurpose gel for vaginal dryness with direct and delayed effect Download PDFInfo
- Publication number
- WO2012076409A1 WO2012076409A1 PCT/EP2011/071612 EP2011071612W WO2012076409A1 WO 2012076409 A1 WO2012076409 A1 WO 2012076409A1 EP 2011071612 W EP2011071612 W EP 2011071612W WO 2012076409 A1 WO2012076409 A1 WO 2012076409A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- colostrum
- factors
- growth factor
- compositions
- factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Definitions
- the present invention relates to topical vaginal compositions in gel form containing immune mediators, growth factors, chemotactic factors and antibacterial/antiviral factors extracted from bovine colostrum, and optionally other ingredients with complementary activity.
- the vaginal ecosystem is a dynamic balance of microbial flora modulated by the hormone balance, the pH and the immune response, which are closely interdependent factors.
- the cells of the vaginal wall play an important role in maintaining said balance, especially the surface and intermediate layers of the epithelium, whose proliferation and maturity is hormone-related.
- vaginal mucosa is normally moistened by fluid, visible on inspection as a clear secretion consisting of plasma transudate, cervical mucus and vestibular gland secretions. Said fluid also contains antimicrobial substances which give it the function of a protective interface. 5% of the vaginal secretion consists of vaginal transudate, and 95% of cervical mucus and the secretions that flow into it. The mucus prevents microbial colonisation by means of mechanical action, through its properties of viscosity and elution, and because it contains antibodies (IgG and IgA), cytokines and antibacterial factors.
- Vaginal dryness is a frequent condition at menopausal age; it is less common but equally unpleasant when it affects patients of childbearing age.
- menopausal hypoestrogenism and urinary habits are the prevalent factors in elderly women, in women of childbearing age the causes can also be represented by the use of low-dose combined oestrogen-progestogen contraceptives, tampons, stress, etc..
- the symptoms consist of pain, stinging and itching, particularly during sexual intercourse, and tend to persist. Bartolini's and Skene's glands should produce mucus; this is essential as a "lubricating fluid", which is useful for normal performance of sexual intercourse.
- this production does not take place, thus causing discomfort for the patient. Poor vaginal and vulvar lubrication often causes a series of disorders in women, such as stinging, itching and dyspareunia. There is also greater sensitivity to even modest irritant stimuli, and more frequent episodes of vaginosis and vaginitis.
- the disorder is quite frequently associated with urination disorders, in the form of urinary stinging. A frequent colposcopy finding is irregular iodine uptake on the Schiller Test.
- a formulation containing, as active ingredient, a colostrum fraction enriched with immunoglobulins, growth factors, chemotactic factors and antibacterial/antiviral factors, partly in free, prompt-release form and partly in controlled-release form, preferably encapsulated in mucoadhesive microbeads.
- Mucoadhesive microspheres are commercially available under the name SPHERULITE®, or can be prepared according to WO 2010060886.
- compositions according to the invention preferably contain other ingredients, especially panthenol, betaine, sericin, vitamin E, Lepidium mehenii (Maca) extract, and Aloe vera.
- compositions according to the invention are advantageously used to treat premenopausal, menopausal and hysterectomised women, teenage girls, postpartum or breast-feeding women, women suffering from stress-related dryness and women who make excessive use of imbalanced local treatments.
- the colostrum fraction usable in the gel according to the invention is obtainable from bovine colostrum, in particular from Holstein (Friesian) and Guernsey cows. It has been demonstrated that these cows produce the colostrum with the highest concentration of growth factors, immune modulators, chemotactic factors and antibacterial/antiviral factors.
- the cows are preferably calving for the second or third time.
- the colostrum is preferably collected between the 5th and 6th hour after calving (colostrum 5H), because the highest concentration of active substances is found during that period.
- the colostrum collected in the first hour contains a lower concentration of active substances, while from the sixth hour onwards the active factors decline rapidly (only 15% are present 24 hours after calving).
- the colostrum 5H collected is tested for tuberculosis, cytoxocity on cell cultures, mycoplasma, prions and human and bovine viruses.
- the colostrum in the udder cistern is practically sterile, but once milked, despite all precautions, due to the high concentration of growth factors, its bacteria count rises very rapidly during freezing and thawing, which are rather slow processes in view of the high density of colostrum in the first few hours (Fig. 1).
- the concentration of preservatives allowed for dietary use and those allowed for parenteral and/or intravenous use is not sufficient to stop the bacteria count.
- the use of ⁇ rays only produces sterile colostrum if radiation exceeding 10 Kgy is used, but this destroys a large part of the active factors, and in any event this method does not prevent the formation of pyrogens, the intravenous and/or topical use of which is prohibited in areas in contact with the blood and lymph nodes.
- An innovative collection system has therefore been devised to obtain a sterile, allergen-free compound, without preservatives or pyrogens.
- Antiseptic agents in sufficient quantities to guarantee sterility and absence of pyrogens are added to the colostrum collected in sterile tanks (which are sterilised empty at 25 Kgy) ( Figure 2).
- Potassium sorbate and sodium benzoate are preferably used, each at the concentration of 12.5% (a much higher concentration than normally used, namely 0.2%), or alternatively, phenoxyethanol at the concentration of 2.5% or diazolidinyl urea at the concentration of 1% ( Figure 3).
- the colostrum thus treated does not need to be stored frozen before the active factor extraction processes, which leads to an obvious saving of industrial costs.
- the colostrum is then diluted with saline solution: this dilution not only gives better filtration without clogging the filter pores, but above all allows the release of active factors bonded to fats and casein.
- the colostrum thus diluted undergoes tangential microfiltration (ceramic membranes with a cut-off between 2 and 6 ⁇ , temperature 5/20°C, transmembrane pressure between 0.2 and 2 bars), which may be repeated, to obtain an opalescent solution free of casein, fat matrix and milk proteins. All these substances constitute over 90% of the allergic content of colostrum and cow's milk.
- the solution is then passed through membranes, or alternatively a molecular sieve with a cut-off at 300,000 daltons, for further purification of the active factors, all weighing less than 200,000 daltons.
- the solution is then dialysed by ultrafiltration (cut-off 1000/2000 daltons) at high pressure to totally eliminate the preservatives (molecular weight under 150 daltons), and then immediately freeze-dried (Fig. 4).
- the result is a sterile, pyrogen-free, preservative-free, anallergic powder (casein and lactoalbumin are responsible for over 95% of allergies to cow's milk) of very high solubility, with the maximum possible concentration of active factors.
- LIFEINSIDETM Mucosa contains the following factors:
- Immunoglobulins of class IgG2 and IgA (a/mg), in the proportion of approx. 60% of the LifeinsideTM Mucosa content (approx. 50% IgG2 and approx. 10% IgA), with natural specificity against many bacteria and viruses, some of which are responsible for superimposed NEC infection.
- COMPLEMENT C3/C4 The complement consists of circulating proteins able to interact with the biological membranes and with specific receptors situated on the surface of various cell types, which induce inflammatory reactions that help combat infection.
- GROWTH FACTORS TGF-pi- TRANSFORMING GROWTH FACTOR stimulates the production of Class A immunoglobulins, which are responsible for immune defences in the mucosa. Modulates cell proliferation and stimulates the deposit of extracellular matrix.
- EGF - EPIDERMAL GROWTH FACTOR regulates the development of the mucosa. Promotes the formation of epithelial cells.
- IGF 1 - INSULIN-LIKE GROWTH FACTOR modulates cell proliferation, adhesion and migration and induces maturity of the mucosa.
- VEGF - VASCULAR ENDOTHELIAL GROWTH FACTOR stimulates blood vessel production. Presents mitogenic activity and activation of vascular permeability.
- FGF-b - FIBROBLAST GROWTH FACTOR BASIC stimulates proliferation of cells of mesenchymal origin such as fibroblasts, endothelial cells, astrocytes and keratinocytes. Acts as a chemotactic and phytogenetic factor.
- GH - GROWTH HORMONE general growth factor of all tissues.
- NGF - NERVE GROWTH FACTOR stimulates activity and regulates growth and differentiation of the sympathetic system.
- PRP- Proline Rich Protein Stimulates maturity of the T cells and has a regenerating effect on the nervous system, the bone system and the mucosa.
- EOTAXIN binds to the chemokine receptors to recruit eosinophils to inflamed tissues.
- IP-10-Chemochin ligand 10 induced by interferon gamma, and aggregates inflammatory cells.
- MCP- 1 Monocyte chemotactic factor- 1 : promotes aggregation of monocytes to inflamed tissues.
- IL-2 induces proliferation of T lymphocytes.
- IL-4 possesses anti-inflammatory activity.
- IL-6 stimulates innate and adaptive immunity.
- IL-9 regulator of haemopoietic cells, stimulates cell proliferation and prevents apoptosis.
- IL-17 regulates the activities of NF-KB and boosts nitric oxide (NO) production.
- IL-10 presents pleiotropic effects in immunoregulation and inflammation. Improves B cell survival, and therefore antibody production. Studies conducted on Knockout mice demonstrate that this protein is essential in immunoregulation of the mucosa.
- Interferon-gamma presents known antiviral, antitumoral and immunoregulatory activities. Is a powerful macrophage activator, and activates cell-mediated activity against bacteria and viruses.
- TNF-a - Tumour necrosis factor stimulates the migration of neutrophils and monocytes to the site of infection.
- fraction containing the substances listed above can be advantageously associated with other compounds with complementary or otherwise useful activity.
- the following substances are preferred:
- Betaine (trimethylglycine) is a substance of plant origin extracted from sugarbeet. It is involved in transmethylation, the biochemical process essential for cell metabolism via which methyl groups (CH3) are transferred from one molecule to another. In the body, betaine loses a methyl group and is converted to dimethylglycine (vitamin B 15); during this process, energy is produced, which is believed to be responsible for the beneficial effects of this compound: disappearance of inexplicable tiredness and favourable effect on the circulatory system, heart, allergies and cell respiration. Betaine is an ideal ingredient for products designed for the skin and mucosa, which are particularly sensitive and delicate, in view of its moisturising and wetting properties, which are useful to promote immediate moisturising of the vaginal mucosa.
- Panthenol Pantothenic acid and the corresponding reduced form, panthenol, is one of the vitamins most widely used in topical applications. It has proved effective as a softener, moisturiser and conditioner. It performs a number of essential functions:
- Vitamin E or tocopherol a fat-soluble vitamin with marked antioxidant activity able to prevent the breakdown of vitamin A and fatty acids, with consequent formation of toxic catabolites and formation of free radicals and peroxides.
- Vitamin E enters the cellular respiration processes, fortifies the walls of the blood vessels, and has important favourable effects on the reproductive apparatus.
- Sericin (MW 400,000): moisturising, film-forming, with acidity buffering ability. Reduces the aggressiveness of surfactants. Has a considerable affinity for hydrophobic proteins and excellent ability to retain water, both of which characteristics increase with molecular weight. Unlike hyaluronic acid, which is often used in vaginal moisturising products, the film-forming effect is not occlusive. In the case of intact sericin, the pleasant, therapeutic film-forming effect does not prevent the other factors from being absorbed by the vaginal mucosa.
- Maca (Lepidium meyenii extract): is a little-known plant remedy and high-energy food. Its popularity is increasing due to its energy-giving, fertility-promoting and aphrodisiac effects. Maca extract contains glucosinolates and isothiocyanates with chemopreventive activity. In women, Maca extract promotes fertility, stimulates the libido, alleviates the symptoms associated with the menopause, attenuates menstrual pain and has an energising effect.
- the constituents of Maca have no oestrogenic activity, as demonstrated in oestrogen-dependent breast cancer (MCF-7 tumour cells).
- Aloe vera has useful regenerating, proteolytic, wound-healing, anti-inflammatory, antipyretic, analgesic, wetting, bacteriostatic, virustatic, fungicidal and anti-itching properties.
- the gel formulations according to the invention are prepared according to known techniques, using conventional excipients.
- the concentration of colostrum fraction in free form can vary between 1 and 10%, while that in encapsulated controlled-release form varies between 0.1 and 5%.
- Aloe vera extract 1-5% Vitamin E: 0.1-2%
- Example 1 Qualitative and quantitative composition of a vaginal gel with rapid and slow release of active factors
- vaginal gel described in Example 1 was used on 30 fertile, premenopausal and menopausal women suffering from vaginal dryness due to hormonal or mechanical reasons, stress, unbalanced local treatments, breast-feeding, contraceptives, etc.
- Table 1 shows the results of colposcopy with the Schiller Test on a group of 30 treated patients and 28 controls. The difference between the two groups at the end of the study was statistically significant (p ⁇ 0.05).
- Table 2 shows the results for the presence and severity of vaginal dryness in the same groups. Once again, the difference was statistically significant (p ⁇ 0.05, treatment with a single daily administration for 20 days).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013006406A MX341572B (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect. |
SI201131168A SI2648739T1 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
US13/992,037 US9248151B2 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
EA201390663A EA026198B1 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
ES11799655.3T ES2624766T3 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
LTEP11799655.3T LT2648739T (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
CA2820403A CA2820403C (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
EP11799655.3A EP2648739B1 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
CN201180058716.1A CN103338778B (en) | 2010-12-09 | 2011-12-02 | The Multipurpose gel for having directly and postponing effect for colpoxerosis |
RS20170416A RS55910B1 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
MEP-2017-99A ME02665B (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
JP2013542470A JP6120774B2 (en) | 2010-12-09 | 2011-12-02 | Versatile gel for vaginal dryness with direct and delayed effects |
BR112013014081-0A BR112013014081B1 (en) | 2010-12-09 | 2011-12-02 | TOPICAL VAGINAL COMPOSITIONS IN THE FORM OF GEL |
AU2011340757A AU2011340757B2 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
DK11799655.3T DK2648739T3 (en) | 2010-12-09 | 2011-12-02 | Multifunctional gel for vaginal dryness with direct and delayed effect |
IL226764A IL226764A (en) | 2010-12-09 | 2013-06-06 | Multipurpose gel for vaginal dryness with direct and delayed effect |
ZA2013/04147A ZA201304147B (en) | 2010-12-09 | 2013-06-06 | Multipurpose gel for vaginal dryness with direct and delayed effect |
CY20171100438T CY1118832T1 (en) | 2010-12-09 | 2017-04-13 | MULTIPLE DOUBLE GEL FOR VINCIAL DRYING WITH IMMEDIATE AND REDUCED EFFECT |
HRP20170663TT HRP20170663T1 (en) | 2010-12-09 | 2017-05-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2010A002260A IT1405998B1 (en) | 2010-12-09 | 2010-12-09 | MULTIPURPOSE GEL AGAINST THE VAGINAL DRYNESS WITH A DIRECT AND DELAYED EFFECT |
ITMI2010A002260 | 2010-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012076409A1 true WO2012076409A1 (en) | 2012-06-14 |
Family
ID=43736916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/071612 WO2012076409A1 (en) | 2010-12-09 | 2011-12-02 | Multipurpose gel for vaginal dryness with direct and delayed effect |
Country Status (26)
Country | Link |
---|---|
US (1) | US9248151B2 (en) |
EP (1) | EP2648739B1 (en) |
JP (1) | JP6120774B2 (en) |
CN (1) | CN103338778B (en) |
AU (1) | AU2011340757B2 (en) |
BR (1) | BR112013014081B1 (en) |
CA (1) | CA2820403C (en) |
CO (1) | CO6781483A2 (en) |
CY (1) | CY1118832T1 (en) |
DK (1) | DK2648739T3 (en) |
EA (1) | EA026198B1 (en) |
ES (1) | ES2624766T3 (en) |
HR (1) | HRP20170663T1 (en) |
HU (1) | HUE033257T2 (en) |
IL (1) | IL226764A (en) |
IT (1) | IT1405998B1 (en) |
LT (1) | LT2648739T (en) |
ME (1) | ME02665B (en) |
MX (1) | MX341572B (en) |
MY (1) | MY160610A (en) |
PL (1) | PL2648739T3 (en) |
PT (1) | PT2648739T (en) |
RS (1) | RS55910B1 (en) |
SI (1) | SI2648739T1 (en) |
WO (1) | WO2012076409A1 (en) |
ZA (1) | ZA201304147B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014202550A3 (en) * | 2013-06-17 | 2015-04-23 | Hestia Investments | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa |
WO2017089475A1 (en) | 2015-11-25 | 2017-06-01 | Nathura S.P.A. | Cicatrizing pharmaceutical composition for topical use |
EP3311806A1 (en) * | 2016-10-21 | 2018-04-25 | Louis Johan Wagenaar | Composition for repair of the mucous membrane |
WO2022223573A1 (en) * | 2021-04-23 | 2022-10-27 | Thomas Meneghini | Disinfectant and use thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2797609T3 (en) | 2011-12-30 | 2017-01-09 | Innomed S A | COMBINING growth factors, cytokines, anti-bacterial / ANTIVIRALS FACTORS STEM CELL-STIMULATING FACTORS, complement C3A / C4A, immunoglobulins, and chemotactic factors |
CN105030872A (en) * | 2015-07-30 | 2015-11-11 | 太阳树(厦门)生物工程有限公司 | Extraction process for Maca extractive |
CN107693842B (en) * | 2017-12-05 | 2020-05-05 | 湖北美尔丽生物科技有限公司 | Medical water-resistant gel and preparation method thereof |
IT201800002990A1 (en) * | 2018-02-23 | 2019-08-23 | Biomedical Res Srl | COMPOSITION BASED ON A MIXTURE OF BIOLOGICAL FACTORS ISOLATED FROM COLOSTRUM AND OZONIZED VEGETABLE OILS FOR USE IN THE TREATMENT OF VAGINITIS AND VAGINOSIS |
CN112135621A (en) * | 2018-05-04 | 2020-12-25 | 宝洁公司 | Compositions and methods for treating vaginal atrophy |
CN112088010A (en) * | 2018-05-04 | 2020-12-15 | 宝洁公司 | Compositions and methods for treating vaginal dryness |
EP3603626A1 (en) * | 2018-07-31 | 2020-02-05 | Mucosa Innovations, S.L. | Composition for use in the prevention and/or treatment of the genitourinary mucosa |
RS58997B1 (en) | 2018-09-14 | 2019-08-30 | Fazlagic Amira Dr | Composition against aging of the intimate area skin |
CN111744005B (en) * | 2020-06-24 | 2024-04-26 | 黑龙江天龙药业有限公司 | Female lower genital tract mucosa protecting and regenerating spray and preparation method thereof |
CN112999335A (en) * | 2021-02-26 | 2021-06-22 | 王利琼 | Preparation method of anti-HPV slow-release hydrogel for preventing and treating various gynecological inflammations in female vagina |
CN114588252A (en) * | 2022-04-08 | 2022-06-07 | 暨南大学附属第一医院(广州华侨医院) | Composition for relieving vaginal atrophy and xerosis and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215506A1 (en) * | 2002-05-17 | 2003-11-20 | Kuhrts Eric H | Methods and compositions for enhancement of creatine transport |
WO2004089278A2 (en) * | 2003-04-09 | 2004-10-21 | Dolhay Klinika Egészségügyi Kft. | Sexual hygienic composition |
WO2007039124A2 (en) * | 2005-09-23 | 2007-04-12 | You Biomedical Research S.R.L | Compositions comprising colostrum and hyaluronic acid for the treatment of vaginal dryness |
WO2008003688A1 (en) * | 2006-07-03 | 2008-01-10 | Jean-Paul Perraudin | Antimicrobial composition and uses thereof |
WO2009113065A1 (en) * | 2008-03-13 | 2009-09-17 | Hadasit Medical Research Services & Development Ltd. | Immuno-modulating compositions for the treatment of immune-mediated disorders |
WO2010060886A2 (en) | 2008-11-25 | 2010-06-03 | Pharmafilm S.R.L. | Mouthwash in the form of a stable suspension comprising microspheres that incorporate an active ingredient |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0177223B1 (en) * | 1984-09-24 | 1990-02-28 | Michael Mezei | Pharmaceutical multi-phase composition |
CN1557340A (en) * | 2004-01-15 | 2004-12-29 | 高春平 | Growth factor and immuneglobin preparation |
EP1802287A2 (en) * | 2004-09-27 | 2007-07-04 | Sigmoid Biotechnologies Limited | Minicapsule formulations |
US8703198B2 (en) * | 2005-03-02 | 2014-04-22 | Aquatrove Biosciences | Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof |
CN101171261A (en) * | 2005-05-10 | 2008-04-30 | 墨累古尔本合作有限公司 | Immunoglobulin fraction and process therefor |
KR100509681B1 (en) * | 2005-05-27 | 2005-08-23 | 주식회사 렉스진바이오텍 | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey |
CA2896083A1 (en) * | 2005-12-08 | 2007-06-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US8268347B1 (en) * | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
JP2009190994A (en) * | 2008-02-13 | 2009-08-27 | Kitasato Institute | Anti-influenza virus agent and method for producing its active ingredient |
EP2280999B1 (en) * | 2008-05-15 | 2017-09-06 | Biosys Health Inc. | Process for producing milk fractions rich in secretory immunoglobulins |
-
2010
- 2010-12-09 IT ITMI2010A002260A patent/IT1405998B1/en active
-
2011
- 2011-12-02 RS RS20170416A patent/RS55910B1/en unknown
- 2011-12-02 WO PCT/EP2011/071612 patent/WO2012076409A1/en active Application Filing
- 2011-12-02 LT LTEP11799655.3T patent/LT2648739T/en unknown
- 2011-12-02 PL PL11799655T patent/PL2648739T3/en unknown
- 2011-12-02 SI SI201131168A patent/SI2648739T1/en unknown
- 2011-12-02 MX MX2013006406A patent/MX341572B/en active IP Right Grant
- 2011-12-02 CA CA2820403A patent/CA2820403C/en active Active
- 2011-12-02 PT PT117996553T patent/PT2648739T/en unknown
- 2011-12-02 AU AU2011340757A patent/AU2011340757B2/en active Active
- 2011-12-02 CN CN201180058716.1A patent/CN103338778B/en active Active
- 2011-12-02 ME MEP-2017-99A patent/ME02665B/en unknown
- 2011-12-02 HU HUE11799655A patent/HUE033257T2/en unknown
- 2011-12-02 EP EP11799655.3A patent/EP2648739B1/en active Active
- 2011-12-02 US US13/992,037 patent/US9248151B2/en active Active
- 2011-12-02 MY MYPI2013002081A patent/MY160610A/en unknown
- 2011-12-02 DK DK11799655.3T patent/DK2648739T3/en active
- 2011-12-02 EA EA201390663A patent/EA026198B1/en unknown
- 2011-12-02 JP JP2013542470A patent/JP6120774B2/en active Active
- 2011-12-02 BR BR112013014081-0A patent/BR112013014081B1/en active IP Right Grant
- 2011-12-02 ES ES11799655.3T patent/ES2624766T3/en active Active
-
2013
- 2013-06-06 CO CO13137403A patent/CO6781483A2/en not_active Application Discontinuation
- 2013-06-06 ZA ZA2013/04147A patent/ZA201304147B/en unknown
- 2013-06-06 IL IL226764A patent/IL226764A/en active IP Right Grant
-
2017
- 2017-04-13 CY CY20171100438T patent/CY1118832T1/en unknown
- 2017-05-02 HR HRP20170663TT patent/HRP20170663T1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215506A1 (en) * | 2002-05-17 | 2003-11-20 | Kuhrts Eric H | Methods and compositions for enhancement of creatine transport |
WO2004089278A2 (en) * | 2003-04-09 | 2004-10-21 | Dolhay Klinika Egészségügyi Kft. | Sexual hygienic composition |
WO2007039124A2 (en) * | 2005-09-23 | 2007-04-12 | You Biomedical Research S.R.L | Compositions comprising colostrum and hyaluronic acid for the treatment of vaginal dryness |
WO2008003688A1 (en) * | 2006-07-03 | 2008-01-10 | Jean-Paul Perraudin | Antimicrobial composition and uses thereof |
WO2009113065A1 (en) * | 2008-03-13 | 2009-09-17 | Hadasit Medical Research Services & Development Ltd. | Immuno-modulating compositions for the treatment of immune-mediated disorders |
WO2010060886A2 (en) | 2008-11-25 | 2010-06-03 | Pharmafilm S.R.L. | Mouthwash in the form of a stable suspension comprising microspheres that incorporate an active ingredient |
Non-Patent Citations (4)
Title |
---|
ALBERTINI B ET AL: "Polymer-lipid based mucoadhesive microspheres prepared by spray-congealing for the vaginal delivery of econazole nitrate", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 20090302 NL LNKD- DOI:10.1016/J.EJPS.2008.12.009, vol. 36, no. 4-5, 2 March 2009 (2009-03-02), pages 591 - 601, XP002654470, ISSN: 0928-0987 * |
BOJKOVSKI J ET AL: "Colostrum composition before and after calving in Holstein-Friesian cows", VETERINARY RECORD, BRITISH VETERINARY ASSOCIATION, LONDON, GB, vol. 156, no. 23, 4 June 2005 (2005-06-04), pages 744 - 745, XP009157091, ISSN: 0042-4900 * |
CHOWDARY K P R ET AL: "Mucoadhesive microspheres for controlled drug delivery", BIOLOGICAL AND PHARMACEUTICAL BULLETIN 200411 JP LNKD- DOI:10.1248/BPB.27.1717, vol. 27, no. 11, November 2004 (2004-11-01), pages 1717 - 1724, XP002654468, ISSN: 0918-6158 * |
PATIL SANJAY B ET AL: "Mucoadhesive microspheres: a promising tool in drug delivery.", CURRENT DRUG DELIVERY OCT 2008 LNKD- PUBMED:18855602, vol. 5, no. 4, October 2008 (2008-10-01), pages 312 - 318, XP002654469, ISSN: 1567-2018 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014202550A3 (en) * | 2013-06-17 | 2015-04-23 | Hestia Investments | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa |
WO2017089475A1 (en) | 2015-11-25 | 2017-06-01 | Nathura S.P.A. | Cicatrizing pharmaceutical composition for topical use |
EP3311806A1 (en) * | 2016-10-21 | 2018-04-25 | Louis Johan Wagenaar | Composition for repair of the mucous membrane |
WO2022223573A1 (en) * | 2021-04-23 | 2022-10-27 | Thomas Meneghini | Disinfectant and use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011340757B2 (en) | Multipurpose gel for vaginal dryness with direct and delayed effect | |
CN112165960A (en) | Composition for treating chronic wounds | |
US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
US20130108599A1 (en) | Herbal Vaginal Compositions | |
JP6139562B2 (en) | Combination of growth factors, cytokines, antibacterial / antiviral factors, stem cell stimulating factors, complement proteins C3A / C4A, immunoglobulins and chemotactic factors | |
US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
CN101912518A (en) | Kidney-tonifying and yang-strengthening capsule | |
CN106581439A (en) | Traditional Chinese medicine composition for treating wounds, diabetic feet and skin ulceration, and preparation method thereof | |
TW200942270A (en) | Chinese medicine composition for treatment of wounds or bedsore, and method for producing preparation thereof | |
ES2964356T3 (en) | Composition based on a mixture of biological factors isolated from colostrum and ozonated vegetable oils for use in the treatment of vaginitis and vaginosis | |
RU2611400C2 (en) | Wound healing gel for external application | |
US20120083747A1 (en) | Vaginal renewal complex and applicator | |
CN1112003A (en) | Health sticker for lactation | |
WO2019194775A2 (en) | A composition for the treatment of diseases of nipple and areola | |
Bałan et al. | Review paper Immunotropic activity of Echinacea. Part II. Experimental and clinical data | |
CN114886922A (en) | Medicine containing fat micro-segment and application thereof in treatment of chronic wound surface difficult to heal | |
Saputri et al. | Breast-Pren (Pain Relief) as a Natural Compress Innovation to Reduce Milk Damage in Breastfeeding Mothers | |
CN104147246A (en) | Instant medicine for treating chronic eczema and preparation method thereof | |
CN110433236A (en) | A kind of Chinese medicine composition and its preparation method and application promoting wound healing | |
CN103239593B (en) | Chinese medicine effective part composition for treating chronic prostatitis and preparation method of Chinese medicine effective part composition | |
CN114522203A (en) | Antibacterial, moisturizing and tightening multifunctional integrated gel and preparation method thereof | |
CN100336518C (en) | Chinese medicine external-application oil agent for treating skin and external disease | |
WO2019038766A1 (en) | Medicinal product for the treatment of trophic ulcers as well as wounds and burns of various origins | |
RO130615A2 (en) | Lymphatic drainage phototherapy product | |
CN103417756A (en) | Medicine for treatment of primary renal vein stenosis in renal transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11799655 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2011799655 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013542470 Country of ref document: JP Kind code of ref document: A Ref document number: 2820403 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13137403 Country of ref document: CO Ref document number: MX/A/2013/006406 Country of ref document: MX Ref document number: 201390663 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13992037 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2011340757 Country of ref document: AU Date of ref document: 20111202 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013014081 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013014081 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130606 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2017/0416 Country of ref document: RS |